AN EVALUATION OF FINANCIAL PERFORMANCE AND HEALTH OF PT PHAPROS TBK IN COMPARISON TO OTHER PHARMACEUTICAL COMPANIES

• Main Author: Febri Hanaan, Aisyah
• Format: Final Project
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/49633
• Institution: Institut Teknologi Bandung

Since 2012, the pharmaceutical market in Indonesia has grown due to the Indonesia government's initiation into universal healthcare, which can increase the accessibility of healthcare and improve the pharmaceutical industry in Indonesia. One of Indonesia's pharmaceutical companies is PT Phapros Tbk, which was already listed in 2018 as a public company and acquired in March 2019 by Kimia Farma (Persero) Tbk. PT Phapros Tbk has a problem in 2019, which decreases net profit when the revenue rises compared to the previous year. Additionally, PT Phapros Tbk's stock price declines after the acquisition. The decline in stock price might, however, be related to the decline in profitability. Hence, PT Phapros Tbk's financial performance assessment should be done to know PT Phapros Tbk 's real financial condition. PT Phapros Tbk will also be compared with other pharmaceutical companies which already listed as public companies. This research's methodology will use the comparison of financial ratios with both time series analysis and cross-sectional analysis, DuPont analysis, and also the BUMN Framework. PT Phapros Tbk 's assessment results in the 2015-2019 period show that it has poor financial performance compared to other firms. PT Phapros Tbk does, however, have good financial performance based on the DuPont analysis. PT Phapros Tbk also considered a healthy company with a rating of A. The findings of this research are expected to be used as consideration in the improvement of PT Phapros Tbk 's financial performance and condition.